Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Zollinger-Ellison Syndrome 1Vomiting 1Prostatic Neoplasms 1Pancreatitis 1Pancreatic Neoplasms 1Ototoxicity 1Osteosarcoma 1Neoplasm Metastasis 1Gastrinoma 1Duodenal Neoplasms 1Breast Neoplasms 1

Interventions

Capecitabine 4Temozolomide 3Octreotide 3Streptozocin 2Fluorouracil 2Everolimus 2vatalanib 1romidepsin 1regorafenib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Omeprazole 1Leucovorin 1Irinotecan 1Gefitinib 1Doxorubicin 1Cisplatin 1Bortezomib 1Biological Therapy 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrinoma × Pantoprazole × Clear all
NCT00001191 2017-07-02

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

National Institutes of Health Clinical Center (CC)

Phase 2 Completed

Zollinger-Ellison Syndrome, Gastrinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡